Kinetics of viral load and antibody response in relation to COVID-19 severity
- 1 October 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 130 (10), 5235-5244
- https://doi.org/10.1172/jci138759
Abstract
The SARS-CoV-2 is the causative agent for COVID-19 pneumonia. Little is known about the kinetics, tissue distribution, cross-reactivity and neutralization antibody response in COVID-19 patients. Two groups of RT-PCR confirmed COVID-19 patients were enrolled in this study, including 12 severe patients in ICUs who needed mechanical ventilation and 11 mild patients in isolation wards. Serial clinical samples were collected for laboratory detection. Results showed that most of the severe patients had viral shedding in a variety of tissues for 20~40 days post onset of disease (8/12, 66.7%); while the majority of mild patients had viral shedding restricted to the respiratory tract and had no detectable virus RNA after 10 days post-onset (9/11, 81.8%). Mild patients showed significantly lower IgM response compared with that of the severe group. IgG responses were detected in most patients in both severe and mild groups at 9 days post onset and remained high level throughout the study. Antibodies cross-reactive to SARS-CoV and SARS-CoV-2 were detected in COVID-19 patients but not in MERS patients. High-levels of neutralizing antibodies were induced after about 10 days post onset in both severe and mild patients which were higher in the severe group. SARS-CoV-2 pseudotype neutralization test and focus reduction neutralization test with authentic virus showed consistent results. Sera from COVID-19 patients, but not convalescent SARS and MERS patients inhibited SARS-CoV-2 entry. Anti-SARS-CoV-2 S and N IgG level exhibited moderate correlation with neutralization titers in patients’ plasma. This study improves our understanding of immune response in human after SARS-CoV-2 infection.Funding Information
- the national key Research and Development Program of China (The National Key Research, Development Program of China)
- the emergency grants for prevention and control of SARS-CoV-2 of Ministry of Science and Technology (2020YFC0841400)
- Guangdong Province Basic and Applied Basic Research Fund (2020A1515010911)
This publication has 23 references indexed in Scilit:
- Epidemiology, Genetic Recombination, and Pathogenesis of CoronavirusesTrends in Microbiology, 2016
- Detection of the Human Coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, JapanJapanese Journal of Infectious Diseases, 2015
- Characterization of Human Coronavirus OC43 and Human Coronavirus NL63 Infections Among Hospitalized Children <5 Years of AgeThe Pediatric Infectious Disease Journal, 2014
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaThe New England Journal of Medicine, 2012
- Development of a Nucleocapsid-Based Human Coronavirus Immunoassay and Estimates of Individuals Exposed to Coronavirus in a U.S. Metropolitan PopulationClinical and Vaccine Immunology, 2008
- The Novel Human Coronaviruses NL63 and HKU1Journal of Virology, 2007
- Croup Is Associated with the Novel Coronavirus NL63PLoS Medicine, 2005
- Antigenic Cross‐Reactivity between Severe Acute Respiratory Syndrome–Associated Coronavirus and Human Coronaviruses 229E and OC43The Journal of Infectious Diseases, 2005
- The Severe Acute Respiratory SyndromeThe New England Journal of Medicine, 2003
- The Morphology of Three Previously Uncharacterized Human Respiratory Viruses that Grow in Organ CultureJournal of General Virology, 1967